Global Celecoxib Capsule Market Research Report 2023

Publication ID:

PB504232144

Publication Date:

April 20, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.
Highlights
The global Celecoxib Capsule market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Celecoxib Capsule is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Celecoxib Capsule is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Celecoxib Capsule in Rheumatoid Arthritis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Celecoxib Capsule include Pfizer, Teva, Mylan, Apotex, Lupin and HENGRUI MEDICINE, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Celecoxib Capsule, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Celecoxib Capsule.
The Celecoxib Capsule market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Celecoxib Capsule market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Celecoxib Capsule companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Teva
Mylan
Apotex
Lupin
HENGRUI MEDICINE
Segment by Type
50mg
100mg
200mg
400mg
Segment by Application
Rheumatoid Arthritis
Osteoarthritis
Acute Pain
Musculoskeletal Pain
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Celecoxib Capsule companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Celecoxib Capsule Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 50mg
1.2.3 100mg
1.2.4 200mg
1.2.5 400mg
1.3 Market by Application
1.3.1 Global Celecoxib Capsule Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Acute Pain
1.3.5 Musculoskeletal Pain
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Celecoxib Capsule Market Perspective (2018-2029)
2.2 Celecoxib Capsule Growth Trends by Region
2.2.1 Global Celecoxib Capsule Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Celecoxib Capsule Historic Market Size by Region (2018-2023)
2.2.3 Celecoxib Capsule Forecasted Market Size by Region (2024-2029)
2.3 Celecoxib Capsule Market Dynamics
2.3.1 Celecoxib Capsule Industry Trends
2.3.2 Celecoxib Capsule Market Drivers
2.3.3 Celecoxib Capsule Market Challenges
2.3.4 Celecoxib Capsule Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Celecoxib Capsule Players by Revenue
3.1.1 Global Top Celecoxib Capsule Players by Revenue (2018-2023)
3.1.2 Global Celecoxib Capsule Revenue Market Share by Players (2018-2023)
3.2 Global Celecoxib Capsule Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Celecoxib Capsule Revenue
3.4 Global Celecoxib Capsule Market Concentration Ratio
3.4.1 Global Celecoxib Capsule Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Celecoxib Capsule Revenue in 2022
3.5 Celecoxib Capsule Key Players Head office and Area Served
3.6 Key Players Celecoxib Capsule Product Solution and Service
3.7 Date of Enter into Celecoxib Capsule Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Celecoxib Capsule Breakdown Data by Type
4.1 Global Celecoxib Capsule Historic Market Size by Type (2018-2023)
4.2 Global Celecoxib Capsule Forecasted Market Size by Type (2024-2029)
5 Celecoxib Capsule Breakdown Data by Application
5.1 Global Celecoxib Capsule Historic Market Size by Application (2018-2023)
5.2 Global Celecoxib Capsule Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Celecoxib Capsule Market Size (2018-2029)
6.2 North America Celecoxib Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Celecoxib Capsule Market Size by Country (2018-2023)
6.4 North America Celecoxib Capsule Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Celecoxib Capsule Market Size (2018-2029)
7.2 Europe Celecoxib Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Celecoxib Capsule Market Size by Country (2018-2023)
7.4 Europe Celecoxib Capsule Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Celecoxib Capsule Market Size (2018-2029)
8.2 Asia-Pacific Celecoxib Capsule Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Celecoxib Capsule Market Size by Region (2018-2023)
8.4 Asia-Pacific Celecoxib Capsule Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Celecoxib Capsule Market Size (2018-2029)
9.2 Latin America Celecoxib Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Celecoxib Capsule Market Size by Country (2018-2023)
9.4 Latin America Celecoxib Capsule Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Celecoxib Capsule Market Size (2018-2029)
10.2 Middle East & Africa Celecoxib Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Celecoxib Capsule Market Size by Country (2018-2023)
10.4 Middle East & Africa Celecoxib Capsule Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Celecoxib Capsule Introduction
11.1.4 Pfizer Revenue in Celecoxib Capsule Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Celecoxib Capsule Introduction
11.2.4 Teva Revenue in Celecoxib Capsule Business (2018-2023)
11.2.5 Teva Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Celecoxib Capsule Introduction
11.3.4 Mylan Revenue in Celecoxib Capsule Business (2018-2023)
11.3.5 Mylan Recent Development
11.4 Apotex
11.4.1 Apotex Company Detail
11.4.2 Apotex Business Overview
11.4.3 Apotex Celecoxib Capsule Introduction
11.4.4 Apotex Revenue in Celecoxib Capsule Business (2018-2023)
11.4.5 Apotex Recent Development
11.5 Lupin
11.5.1 Lupin Company Detail
11.5.2 Lupin Business Overview
11.5.3 Lupin Celecoxib Capsule Introduction
11.5.4 Lupin Revenue in Celecoxib Capsule Business (2018-2023)
11.5.5 Lupin Recent Development
11.6 HENGRUI MEDICINE
11.6.1 HENGRUI MEDICINE Company Detail
11.6.2 HENGRUI MEDICINE Business Overview
11.6.3 HENGRUI MEDICINE Celecoxib Capsule Introduction
11.6.4 HENGRUI MEDICINE Revenue in Celecoxib Capsule Business (2018-2023)
11.6.5 HENGRUI MEDICINE Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Teva
Mylan
Apotex
Lupin
HENGRUI MEDICINE

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂